Related Experiment Videos
Molecular mechanisms in the pathogenesis of traumatic brain injury
S K Ray1, C E Dixon, N L Banik
1Department of Neurology, Clinical Science Building, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 309, Charleston, SC 29425, USA.
Abstract:
Traumatic brain injury (TBI) is a serious neurodisorder commonly caused by car accidents, sports related events or violence. Preventive measures are highly recommended to reduce the risk and number of TBI cases. The primary injury to the brain initiates a secondary injury process that spreads via multiple molecular mechanisms in the pathogenesis of TBI. The events leading to both neurodegeneration and functional recovery after TBI are generalized into four categories: (i) primary injury that disrupts brain tissues; (ii) secondary injury that causes pathophysiology in the brain; (iii) inflammatory response that adds to neurodegeneration; and (iv) repair-regeneration that may contribute to neuronal repair and regeneration to some extent following TBI. Destructive multiple mediators of the secondary injury process ultimately dominate over a few intrinsic protective measures, leading to activation of cysteine proteases such as calpain and caspase-3 that cleave key cellular substrates and cause cell death. Experimental studies in rodent models of TBI suggest that treatment with calpain inhibitors (e.g., AK295, SJA6017) and neurotrophic factors (e.g., NGF, BDNF) can prevent neuronal death and dysfunction in TBI. Currently, there is still no precise therapeutic strategy for the prevention of pathogenesis and neurodegeneration following TBI in humans. The search continues to explore new therapeutic targets and development of promising drugs for the treatment of TBI.
Insights
Traumatic brain injury (TBI) triggers secondary injury cascades, causing neurodegeneration. Research explores calpain inhibitors and neurotrophic factors as potential treatments to prevent cell death and improve outcomes in TBI patients.
Area of Science:
- Neuroscience
- Pathophysiology
- Trauma Research
Background:
- Traumatic brain injury (TBI) is a significant cause of neurodisability, often resulting from accidents or violence.
- TBI initiates a cascade of primary and secondary injury mechanisms, leading to neurodegeneration and impaired functional recovery.
- Current therapeutic strategies for TBI are limited, highlighting the need for novel treatments.
Purpose of the Study:
- To review the molecular mechanisms underlying secondary injury in TBI.
- To explore potential therapeutic targets, including calpain and caspase-3 pathways.
- To discuss the efficacy of experimental treatments like calpain inhibitors and neurotrophic factors in preclinical TBI models.
Main Methods:
- Review of experimental studies on TBI pathogenesis and treatment.
- Analysis of molecular mediators involved in secondary injury, including cysteine proteases.
- Examination of preclinical data on neuroprotective agents in rodent TBI models.
Main Results:
- Secondary injury mediators, such as calpain and caspase-3, contribute significantly to cell death after TBI.
- Experimental treatments with calpain inhibitors (e.g., AK295, SJA6017) and neurotrophic factors (e.g., NGF, BDNF) show promise in preventing neuronal damage in TBI models.
- Despite promising preclinical findings, effective human therapies for TBI prevention and treatment remain elusive.
Conclusions:
- Understanding the complex molecular mechanisms of TBI is crucial for developing effective treatments.
- Calpain inhibitors and neurotrophic factors represent promising therapeutic avenues for mitigating TBI-induced neurodegeneration.
- Further research is needed to translate these experimental findings into clinical applications for human TBI patients.